IIT Bombay Proteomics - Brain_Tumor_marker_MRM

MRM for validation of Brain tumor biomarkers
Data License: CC BY 4.0 | ProteomeXchange: PXD024238
  • Organism: Homo sapiens
  • Instrument: TSQ Altis
  • SpikeIn: No
  • Keywords: Multiple reaction monitoring, brain tumor, cerebrospinal fluid, tumor tissue, biomarkers
  • Lab head: Sanjeeva Srivastava Submitter: Sanjeeva Srivastava
Abstract
The emergence of omics technologies over the last decade has helped in advancement of research and our understanding of complex diseases like brain cancers. However, barring genomics, no other omics technology has been able to find utility in clinical settings. The recent advancements in mass spectrometry instrumentation have resulted in proteomics technologies becoming more sensitive and reliable. Targeted proteomics, a relatively new branch of mass spectrometry-based proteomics has shown immense potential in addressing the shortcomings of the standard molecular biology-based techniques like Western blotting and Immunohistochemistry. In this study we demonstrate the utility of Multiple reaction monitoring (MRM), a targeted proteomics approach, in quantifying peptides from proteins like Apolipoprotein A1 (APOA1), Apolipoprotein E (APOE), Prostaglandin H2 D-Isomerase (PTGDS), Vitronectin (VTN) and Complement C3 (C3) in cerebrospinal fluid (CSF) collected from Glioma and Meningioma patients. Additionally, we also report transitions for peptides from proteins – Vimentin (VIM), Cystatin-C (CST3) and Clusterin (CLU) in surgically resected Meningioma tissues; Annexin A1 (ANXA1), Superoxide dismutase (SOD2) and VIM in surgically resected Glioma tissues; and Microtubule associated protein-2 (MAP-2), Splicing factor 3B subunit 2 (SF3B2) and VIM in surgically resected Medulloblastoma tissues. To our knowledge this is the first study reporting proteins from three types of brain malignancies and two different bio-specimens. Future studies involving a large cohort of samples aimed at accurately detecting and quantifying peptides of proteins with roles in brain malignancies could potentially result in a panel of proteins showing ability to classify and grade tumors. Successful application of these techniques could ultimately offer alternative strategies with increased accuracy, sensitivity and lower turnaround time thus making them translatable to the clinics.
Created on 3/11/21, 11:34 AM
Clustergrammer Heatmap
 
Download
Meningioma_CSF_MRM_2021-02-17_13-51-29.sky.zip2021-03-11 11:32:28515156270
Glioma_CSF_MRM_2021-02-17_13-57-43.sky.zip2021-03-11 11:32:285151564100
Medulloblastoma_MRM_2021-02-17_14-29-27.sky.zip2021-03-11 11:32:28310105390
MCF-7_QC_Analysed_2021-02-17_14-54-14.sky.zip2021-03-11 11:32:282666750
BSA_QC_Analysed_2021-02-17_14-56-13.sky.zip2021-03-11 11:32:281776550
BSA_QC_standard curve_2021-02-17_14-57-03.sky.zip2021-03-11 11:32:281776557
Glioma_tissue_MRM_2021-03-11_17-52-52.sky.zip2021-03-11 11:32:283121210390
Meningioma_tissue_MRM_2021-03-11_19-28-51.sky.zip2021-03-11 11:32:28310108390